Comparison 4. Toxicity ‐ Nausea and vomiting.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1 Nausea and vomiting ‐ asssessable patients ‐ all trials	30	7487	Risk Ratio (M‐H, Random, 95% CI)	1.29 [0.96, 1.74]
4.1.1 Question 1: Regimen A versus A + other	20	5149	Risk Ratio (M‐H, Random, 95% CI)	1.16 [0.81, 1.65]
4.1.2 Question 2: Regimen A versus Regimen C (poly)	10	2338	Risk Ratio (M‐H, Random, 95% CI)	1.79 [0.93, 3.43]
4.2 Nausea and vomiting ‐ Question 1 ‐ Regimen A versus A + other ‐ assessable patients	17	4793	Risk Ratio (M‐H, Random, 95% CI)	1.16 [0.75, 1.80]
4.2.1 Sub‐group A: Single antracycline agent versus anthracycline + other regimen	12	2958	Risk Ratio (M‐H, Random, 95% CI)	1.23 [0.74, 2.05]
4.2.2 Sub group B: Single alkylating versus alkylating + other	1	103	Risk Ratio (M‐H, Random, 95% CI)	2.94 [0.62, 13.90]
4.2.3 Sub group C: Single antimetabolite versus antimetabolite + other	2	246	Risk Ratio (M‐H, Random, 95% CI)	0.44 [0.34, 0.58]
4.2.4 Sub group D: Single taxane versus taxane + other	3	1486	Risk Ratio (M‐H, Random, 95% CI)	1.29 [0.63, 2.65]
4.3 Nausea and vomiting ‐ Question 2 ‐ Regimen A versus Regimen C ‐ assessable patients	9	2082	Risk Ratio (M‐H, Random, 95% CI)	1.45 [0.79, 2.66]
4.3.1 Sub group E: Single anthracycline agent versus non‐anthracycline combination regimen	2	422	Risk Ratio (M‐H, Random, 95% CI)	3.44 [0.11, 104.44]
4.3.2 Sub‐group F: Single taxane versus non‐taxane, non‐anthracycline containing combination regimen	5	1244	Risk Ratio (M‐H, Random, 95% CI)	2.16 [0.78, 6.00]
4.3.3 Sub‐group G: Single non‐taxane, non‐anthracycline agent versus other combination regimen	2	416	Risk Ratio (M‐H, Random, 95% CI)	0.72 [0.31, 1.66]